The Various Shapes of Innovation

[1] Vincent K. Omachonu NGE. Innovation in Healthcare Delivery Systems: A Conceptual Framework. The Public Sector Innovation Journal. 2010; 15(1):1-20.Search in Google Scholar

[2] Lansisalmi H, M. Kivimaki, P. Aalto, and R. Ruoranen. Innovation in Healthcare: A Systematic Review of Recent Research. Nursing Science Quarterly. 2006; 19:66-72.10.1177/089431840528412916407603Search in Google Scholar

[3] Hult KJ. Incremental Innovation and Pharmaceutical Productivity. 2014.Search in Google Scholar

[4] Varkey P, Horne A, Bennet KE. Innovation in health care: a primer. American journal of medical quality : the official journal of the American College of Medical Quality. 2008; 23(5):382-8.10.1177/106286060831769518820143Search in Google Scholar

[5] Ruud E.H.M S, Wouter P.C. Boon. The role of users in innovation in the pharmaceutical industry. Drug Discovery Today. 2008; 13(7/8):353-9.10.1016/j.drudis.2007.12.00618405849Search in Google Scholar

[6] Kaitin KI. The Landscape for Pharmaceutical Innovation: Drivers of Cost-Effective Clinical Research. Pharmaceutical outsourcing. 2010; 2010.Search in Google Scholar

[7] Schulthess D, Chlebus M, Bergstrm R, et al. Medicine adaptive pathways to patients (MAPPs): using regulatory innovation to defeat Eroom’s law. Chinese clinical oncology. 2014; 3(2):21.Search in Google Scholar

[8] Collyar D. CR. A rennaissance in biomedical innovation: global villages raise effective therapies. Future Medicinal Chemistry. 2015; 7:971-9+74.10.4155/fmc.15.4726062394Search in Google Scholar

[9] Montgomery JLaCM. The Pharmaceutical Commons: Sharing and Exclusion in Global Health Drug Development. Science, Technology, & Human Values. 20104; 40(1):3-29.10.1177/0162243914542349436170125866425Search in Google Scholar

[10] Reddy R. The Future of Pharma: A U.S. Sector Review. Cognizant Reports. 2011.Search in Google Scholar

[11] M G. The Innovative Medicines Initiative: A European Response to the Innovation Challenge. Clinical Pharmacology & Therapeutics. 2012; 91(3):418-25.10.1038/clpt.2011.32122318619Search in Google Scholar

[12] The right prevention and treeatment for the right patient at the right time: Strategic Research Agenda for Innovative Medicines Initiative 2. EFPIA. Spring 2014.Search in Google Scholar

[13] Golubnitschaja O, Kinkorova J, Costigliola V. Predictive, Preventive and Personalised Medicine as the hardcore of ‘Horizon 2020’: EPMA position paper. The EPMA journal. 2014; 5(1):6.10.1186/1878-5085-5-6398555124708704Search in Google Scholar

[14] Piccart-Gebhart MJ PM, Leyland-Jones Bet al. The Case for Personalized Medicine. Personalised Medicine Coalition 2009.Search in Google Scholar

[15] Y. Touchefeu KJH, J. P. Galmiche & G. Vassaux. Review article: gene therapy, recent developments and future prospects in gastrointestinal oncology. Alimentary Pharmacology and Therapeutics. 2010; 32:953-68.10.1111/j.1365-2036.2010.04424.x20937041Search in Google Scholar

[16] Misra S. Human gene therapy: a brief overview of the genetic revolution. The Journal of the Association of Physicians of India. 2013; 61(2):127-33.Search in Google Scholar

[17] Patil P.M. CPD, Megha Sahu, Duragkar N.J. REVIEW ARTICLE ON GENE THERAPY. International Journal of Genetics. 2012; 4(1):74-9.10.9735/0975-2862.4.1.74-79Search in Google Scholar

[18] Stevens W, Philipson TJ, Khan ZM, et al. Cancer mortality reductions were greatest among countries where cancer care spending rose the most, 1995-2007. Health affairs. 2015; 34(4):562-70.10.1377/hlthaff.2014.063425847637Search in Google Scholar

[19] Lichtenberg FR. Pharmaceutical Innovation and Longevity Growth in 30 developing high-income countries, 2000-2009. NBER Working Paper Series. 2013.10.3386/w18235Search in Google Scholar

[20] America PRaMo. 2012 Pharmaceutical Industry Profile. 2012.Search in Google Scholar

[21] Twelves C, Gollins S, Grieve R, et al. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2006; 17(2):239-45.10.1093/annonc/mdj02316344278Search in Google Scholar

[22] Edward L. Korn, Boris Freidlin, Jeffrey S. Abrams, and Susan Halabi. Design Issues in Randomized Phase II/III Trials. Journal of Clinical Oncology. Vol 30, No 6, Feb 20 2012.10.1200/JCO.2011.38.5732329556222271475Search in Google Scholar

[23] Peter K. Kimani, Susan Toddb and Nigel Stallarda. Conditionally unbiased estimation inphase II/III clinical trials with early stopping for futility. Statistics in Medicine. 2013, 32 2893–291010.1002/sim.5757381398123413228Search in Google Scholar

[24] Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. Journal of the National Cancer Institute. 2010; 102(3):152–160. [PubMed: 20075367]10.1093/jnci/djp477291104220075367Search in Google Scholar

[25] Ryan D. Gentzler, Sarah E. Yentz, Melissa L. Johnson, Alfred W. Rademaker, and Jyoti D. Patel. The Changing Landscape of Phase II/III Metastatic NSCLC Clinical Trials and the Importance of Biomarker Selection Criteria. Cancer 2014;120:3853-8.10.1002/cncr.2895625155290Search in Google Scholar

[26] Henrik Zetterberg*, Niklas Mattsson, Kaj Blennow and Bob Olsson. Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. Alzheimer’s Research & Therapy 2010, 2:32.10.1186/alzrt56303187821122172Search in Google Scholar

[27] Shein-Chung Chow and Ralph Corey. Benefits, challenges and obstacles of adaptive clinical trial designs. Orphanet Journal of Rare Diseases 2011, 6:79.10.1186/1750-1172-6-79324885322129361Search in Google Scholar

[28] Daniel Schneider, Giampaolo Bianchini, Denis Horgan, Stefan Michiels, Wim Witjes, Robert Hills, Juliette Plun-Favreau, Angela Brand, Mark Lawler. Public Health Genomics 2015;18:349–358.10.1159/00044155626571110Search in Google Scholar

[29] Ada Hang-Heng Wong, Chu-Xia Deng. Precision Medicine for Personalized Cancer Therapy. Int. J. Biol. Sci. 2015, Vol. 11.10.7150/ijbs.14154467199826681920Search in Google Scholar